Oxford Biomedica PLC OXB and PhoreMost enter gene therapy collaboration
November 09 2020 - 1:00AM
RNS Non-Regulatory
TIDMOXB
Oxford Biomedica PLC
09 November 2020
Oxford Biomedica and PhoreMost enter gene therapy discovery
collaboration
-- Collaboration to develop next-generation CAR-T cell therapies
with improved efficacy and durability
-- PhoreMost's SITESEEKER platform will identify active peptides
to be deployed within Oxford Biomedica's LentiVector (R) delivery
system
Oxford, UK - 9 November, 2020 : Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group"), a leading gene and cell
therapy group and PhoreMost Limited ("PhoreMost"), the UK-based
biopharmaceutical company dedicated to developing drugs against
intractable disease targets, today announced that they have entered
into a discovery collaboration to develop next-generation CAR-T
cell therapies. Financial details of the agreement are not
disclosed.
PhoreMost will deploy its in-house expertise and next-generation
phenotypic screening platform, SITESEEKER(R) , to identify
therapeutic candidates for Oxford Biomedica's LentiVector(R) gene
therapy delivery system. The programme will initially focus on
CAR-T therapy and aims to develop next-generation cell therapies
with significantly improved efficacy and durability.
John Dawson, CEO of Oxford Biomedica, said: "We are excited to
apply this next-generation technology to our LentiVector platform.
The collaboration has the potential to deliver more effective CAR-T
therapies, and we look forward to working closely with the
PhoreMost team."
Dr Chris Torrance, CEO, PhoreMost, said: "This collaboration
with Oxford Biomedica, a global pioneer in cell and gene therapies,
is further recognition of the power of SITESEEKER, offering an
exciting opportunity to discover and accelerate the development of
clinical stage products. The natural complementarity between
SITESEEKER and LentiVector offers great promise for this and future
collaborations between the two companies."
SITESEEKER exploits protein shape diversity to find functionally
active peptides linked to any chosen disease setting, significantly
enhancing the power of phenotypic screening and translation into
therapeutic modalities. Based on proprietary protein interference,
or 'PROTEINi(R) ', technology, SITESEEKER is able to systematically
probe the entire proteome in a live cell environment to identify
and exploit novel drug targets.
Oxford Biomedica is a world-leading pioneer of cell and gene
therapies. Its LentiVector(R) platform enables the successful
development of breakthrough gene and cell-based medicines, and
through collaborations with pharmaceutical partners, has delivered
the first FDA and EMA approved CAR-T cell therapy.
-Ends-
Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial T: +44 (0)1865 783 000
Officer T: +44 (0)1865 954 161 / E: ir@oxb.com
Catherine Isted, Head of Corporate
Development & IR
Oxford Biomedica Media enquiries
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal T: +44 (0)20 3709 5700
PhoreMost Ltd
Dr Neil Torbett, CBO E: neil.torbett@phoremost.com
PhoreMost Media enquiries
Zyme Communications
Katie Odgaard E: katie.odgaard@zymecommunications.com
T: +44 (0)7787 502 947
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R)), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb,
Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Beam
Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene
Therapy Consortium and Imperial Innovations, through which it has
long-term economic interests in other potential gene and cell
therapy products. Additionally the group has signed a 3 year master
supply and development agreement with AstraZeneca for large-scale
manufacture of the adeno based COVID-19 vaccine candidate, AZD1222.
Oxford Biomedica is based across several locations in Oxfordshire,
UK and employs more than 580 people. Further information is
available at www.oxb.com
About PhoreMost Ltd
PhoreMost has developed a next-generation phenotypic screening
platform called SITESEEKER(R) that can discern the best new targets
for future therapy and crucially, how to drug them, which has the
potential to significantly increase the diversity and affordability
of novel therapeutics for cancer and other unmet diseases. Based on
the Company's core proprietary 'Protein Interference' technology,
SITESEEKER(R) systematically unmasks cryptic druggable sites across
the entire human genome and directly links them to useful
therapeutic functions in a live-cell context. Using this platform,
PhoreMost is building a pipeline of novel
drug discovery programmes aimed at addressing a range of unmet diseases. www.phoremost.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABFBRTMTIMBTM
(END) Dow Jones Newswires
November 09, 2020 02:00 ET (07:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024